X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Tavo works by optimizing cellular uptake of DNA-based IL-12 recruits and primes immune cancer-fighting cells in the tumor leading to systemic immune responses without systemic toxicity.
Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab
Therapeutic Area: Oncology Product Name: Tavo
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2021
Details:
KEYNOTE-695 is OncoSec's registration-directed Phase 2b trial evaluating TAVO, a DNA plasmid-based interleukin-12 (IL-12) + KEYTRUDA® (pembrolizumab) in patients with rigorously confirmed anti-PD-1 checkpoint resistant metastatic melanoma.
Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab
Therapeutic Area: Oncology Product Name: TAVO
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2021
Details:
The CORVax12 vaccine approach combines the co-administration of OncoSec’s TAVO with a DNA-encodable version of the SARS-CoV-2 spike glycoprotein to boost the immunogenicity of the component developed by NIAID Vaccine Research Center scientists.
Lead Product(s): SARS-CoV-2 spike protein plasmid DNA vaccine,Tavokinogene Telseplasmid
Therapeutic Area: Infections and Infectious Diseases Product Name: CORVax12
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2021
Details:
Through this agreement, Sirtex gains an option to non-exclusively co-promote the Company's lead product candidate, TAVO™ (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S.
Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab
Therapeutic Area: Oncology Product Name: Tavo
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sirtex Medical
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Agreement January 19, 2021
Details:
The applications are directed to the use of OncoSec's interleukin-12 (IL-12)-based immunotherapy platform, including its lead product candidate TAVO™ delivered with the Company's proprietary intratumoral gene electrotransfer system for the treatment of cancer.
Lead Product(s): Tavokinogene Telseplasmid,Undisclosed
Therapeutic Area: Oncology Product Name: Tavo
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Details:
OncoSec will present new positive interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial investigating TAVO™ in combination with KEYTRUDA® in patients with anti-PD-1 checkpoint refractory metastatic melanoma at 35th SITC Annual Meeting.
Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab
Therapeutic Area: Oncology Product Name: Tavo
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2020
Details:
CORVax12 is the first next-generation DNA vaccine candidate to deliver spike (S) protein from SARS-CoV-2 plus immune-stimulating interleukin-12 (IL-12) to elicit T-cell activation and drive robust humoral immunity.
Lead Product(s): SARS-CoV-2 spike protein plasmid DNA vaccine,Tavokinogene Telseplasmid
Therapeutic Area: Infections and Infectious Diseases Product Name: CORVax12
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Patent covers the use of intratumoral electroporation of DNA encoding interleukins to treat cancer and is significant because it is not specific to which type of immune-stimulatory interleukin can be used to treat a patient, nor is it limited to a particular type of cancer.
Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab
Therapeutic Area: Oncology Product Name: Tavo
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
Anti-PD-1 immune checkpoint therapies, such as OPDIVO®, are an established first-line treatment for advanced melanoma, and encouraging clinical data suggest that they have clinically meaningful activity in the neoadjuvant setting as well.
Lead Product(s): Tavokinogene Telseplasmid,Nivolumab
Therapeutic Area: Oncology Product Name: Tavo
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
OncoSec Medical Incorporated presented new data further demonstrating the power of OncoSec's next-generation IL-12 plasmid (TAVOPLUS) therapeutic when combined with a T cell stimulator (TAVOPLUS-CD3) or an enhanced chemokine gradient (TAVOPLUS-CXCL9).
Lead Product(s): Tavokinogene Telseplasmid,Undisclosed
Therapeutic Area: Oncology Product Name: Tavo plus
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
